Quantum BioPharma announces that the Positron Emission Tomography, PET, tracer used in a joint study with Massachusetts General Hospital, MGH, scientists shows the ability to capture differences across lesions in multiple sclerosis, MS, patients, which may prove highly useful for monitoring myelin integrity and demyelination in MS. In this study, (18)3F4AP was found to have excellent properties for imaging the human brain and, critically and importantly, was able to detect differences across lesions not visible by conventional MRI. These findings suggest that the tracer holds significant promise and potential as a key biomarker to monitor changes in demyelination in MS, and, importantly, myelin changes in response to Quantum Biopharma’s investigational and potentially breakthrough neuroprotective drug, Lucid-21-302.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Reports Strong Q2 2025 with Key Developments
- Quantum Group reports Q2 operating expenses $4.9M vs $3.4M last quarter
- Quantum Biopharma Reports Increased Liabilities in Latest Financial Statement
- Quantum BioPharma Reports Positive Phase 1 Results for MS Drug Lucid-MS
- Quantum Group subsidiary received CSR for Phase 1 MAD trial